Exclusive: It Seems Five Prime Therapeutics Inc Will Go Up. Just Reaches 52-Week High

Exclusive: It Seems Five Prime Therapeutics Inc Will Go Up. Just Reaches 52 Week High

The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) hit a new 52-week high and has $63.45 target or 5.00% above today’s $60.43 share price. The 5 months bullish chart indicates low risk for the $1.77 billion company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $63.45 price target is reached, the company will be worth $88.50M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 78,496 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 21.20% since April 22, 2016 and is uptrending. It has outperformed by 15.79% the S&P500.

Analysts await Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings on March, 9. They expect $-0.51 EPS, down 104.80% or $11.14 from last year’s $10.63 per share. After $-0.72 actual EPS reported by Five Prime Therapeutics Inc for the previous quarter, Wall Street now forecasts -29.17% EPS growth.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Five Prime Therapeutics has been the topic of 9 analyst reports since July 31, 2015 according to StockzIntelligence Inc. BMO Capital Markets initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Tuesday, April 12 with “Market Perform” rating. On Tuesday, October 25 the stock rating was initiated by Citigroup with “Buy”. Citigroup initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Friday, July 31 with “Buy” rating. As per Monday, October 19, the company rating was maintained by Oppenheimer. Credit Suisse maintained the shares of FPRX in a report on Friday, March 11 with “Outperform” rating. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) earned “Sell” rating by Zacks on Tuesday, August 11. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. Zacks upgraded Five Prime Therapeutics Inc (NASDAQ:FPRX) on Friday, August 21 to “Sell” rating.

According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”

Insitutional Activity: The institutional sentiment decreased to 1.15 in Q2 2016. Its down 1.14, from 2.29 in 2016Q1. The ratio is negative, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.
Pnc Services has invested 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Vanguard Inc, a Pennsylvania-based fund reported 1.47M shares. Allianz Asset Ag holds 0% or 66,597 shares in its portfolio. Ubs Asset Management Americas last reported 23,721 shares in the company. Driehaus Capital Mngmt Limited Liability Company last reported 135,824 shares in the company. Credit Suisse Ag reported 64,371 shares or 0% of all its holdings. Spark Invest Mngmt Lc reported 148,100 shares or 0.57% of all its holdings. Gsa Cap Llp has 94,425 shares for 0.22% of their US portfolio. Williams Jones Assoc Lc accumulated 11,066 shares or 0.02% of the stock. Moreover, Bancorporation Of Montreal Can has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 25,101 shares. The New York-based Morgan Stanley has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Legal And General Gru Public Ltd Company last reported 4,077 shares in the company. Voya Invest Management Limited holds 11,497 shares or 0% of its portfolio. Great West Life Assurance Com Can last reported 2,346 shares in the company. Royal Retail Bank Of Canada reported 1,000 shares or 0% of all its holdings.

Insider Transactions: Since July 27, 2016, the stock had 0 insider buys, and 6 selling transactions for $1.15 million net activity. RINGO WILLIAM R sold $25,385 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) on Monday, August 1. 8,130 shares were sold by Jensen Peder, worth $449,589 on Wednesday, November 9.

FPRX Company Profile

Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment